Slimmer Rallybio to concentrate on best chance of success

7 February 2024
2020_biotech_lab_vials_big

The long and winding road of biopharma development has taken another turn for Rallybio (Nasdaq: RLYB), with the firm opting to slash almost half of its workforce to preserve cash.

The Connecticut, USA-based firm, which is  working with AbCellera (Nasdaq: ABCL) on antibodies for rare diseases, said the restructuring would enable it to extend its cash runway out to the middle of 2026.

Less than a year ago, the firm switched horses and scrapped its lead candidate to focus on another option targeting neonatal alloimmune thrombocytopenia (FNAIT).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology